HCW Biologics Inc.
Pharmaceutical Preparations · MIRAMAR · FL
Moderate confidence (50%)
Updated Oct 20, 2026, 12:03 AM
What is happening
Derived by rule set status-rules-2026.09.7
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
Latest material event: HCW Biologics Inc. received a delisting notice from its exchange (Jun 29, 2026)
Timeline
Every material event, newest first. History is never overwritten.
HCW Biologics Inc. received a delisting notice from its exchange
Jun 29, 2026
Delisting notice received
- SEC EDGAR — “Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On June 29, 2026, HCW Biologics Inc. (the Company ) received written notice form the Listing Qualifications Staff (the Staff ) of the Nasdaq Capital Market Nasdaq Stock Market LLC ( Nasdaq ) that the Nasdaq Hearings Panel (the Panel ) found that the Company regained compliance with Listing Rule 5550(a)(2), the Bid Price Rule, per the terms set forth in the Panel s decision letter dated May 29, 2026, as amended. As indicated in the Panel s decision letter, as amended, if the Company sa…”
HCW Biologics Inc. received a delisting notice from its exchange
May 29, 2026
Delisting notice received
- SEC EDGAR — “Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, on March 26, 2026, HCW Biologics Inc. (the Company ) received written notice from the Listing Qualifications Staff (the Staff ) of the Nasdaq Stock Market LLC ( Nasdaq ) that for 30 consecutive business days, the Company s listed securities did not maintain a minimum bid price of $1 per share, in accordance with Nasdaq Listing Rule 5550(a)(2) ( Bid Price Rule ) for continued listing on The Nasdaq Capital Market (the Exchange ) . Due to the fact that the Compan…”
HCW Biologics Inc. received a delisting notice from its exchange
Feb 26, 2026
Delisting notice received
- SEC EDGAR — “Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On February 26, 2026, the HCW Biologics Inc. (the Company ) received written notice form the Listing Qualifications Staff (the Staff ) of the Nasdaq Capital Market Nasdaq Stock Market LLC ( Nasdaq ) that the Nasdaq Hearings Panel (the Panel ) found that the Company regained compliance with all continued listing rules of the Nasdaq Capital Market (the Exchange ), according to the terms of the Panel s decision letter dated October 13, 2025. On October 13, 2025, the Panel had granted the…”
Company information
- Founded
- —
- Employees (estimate)
- —
- Industry
- Pharmaceutical Preparations
- Subindustry
- —
- Listing
- SEC lists the ticker HCWB on Nasdaq.
- SEC CIK
- 0001828673
- Website
- —
- —
- Headquarters
- MIRAMAR, FL
- Also known as
- —
- Legal entities
- HCW Biologics Inc.
Sources
Every material source used to build this profile.
SEC Company Submissions (TIER 1 · UNVERIFIED)
HCW Biologics Inc. — Pharmaceutical Preparations (SIC 2834) — MIRAMAR, FL
View source recordSEC EDGAR (TIER 1 · UNVERIFIED)
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, on March 26, 2026, HCW Biologics Inc. (the Company ) received written notice from the Listing Qualifications Staff (the Staff ) of the Nasdaq Stock Market LLC ( Nasdaq ) that for 30 consecutive business days, the Company s listed securities did not maintain a minimum bid price of $1 per share, in accordance with Nasdaq Listing Rule 5550(a)(2) ( Bid Price Rule ) for continued listing on The Nasdaq Capital Market (the Exchange ) . Due to the fact that the Compan…
View source recordSEC EDGAR (TIER 1 · UNVERIFIED)
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On February 26, 2026, the HCW Biologics Inc. (the Company ) received written notice form the Listing Qualifications Staff (the Staff ) of the Nasdaq Capital Market Nasdaq Stock Market LLC ( Nasdaq ) that the Nasdaq Hearings Panel (the Panel ) found that the Company regained compliance with all continued listing rules of the Nasdaq Capital Market (the Exchange ), according to the terms of the Panel s decision letter dated October 13, 2025. On October 13, 2025, the Panel had granted the…
View source recordSEC EDGAR (TIER 1 · UNVERIFIED)
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On June 29, 2026, HCW Biologics Inc. (the Company ) received written notice form the Listing Qualifications Staff (the Staff ) of the Nasdaq Capital Market Nasdaq Stock Market LLC ( Nasdaq ) that the Nasdaq Hearings Panel (the Panel ) found that the Company regained compliance with Listing Rule 5550(a)(2), the Bid Price Rule, per the terms set forth in the Panel s decision letter dated May 29, 2026, as amended. As indicated in the Panel s decision letter, as amended, if the Company sa…
View source record
Status history
Every derived status, with the rule that produced it.
- DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:32 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:11 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 15, 2026, 12:35 PM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 14, 2026, 04:45 PM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- UNKNOWN → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 8, 2026, 03:16 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.